The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Bob Azelby, chief executive officer will be departing the Company and the Board imminently.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.98 USD | +17.40% | +3.38% | +47.41% |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 11 | Top Midday Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
+47.41% | 112M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc